← Back to Search

Monoclonal Antibodies

Radiation + Immunotherapy + PARP Inhibitor for Breast Cancer (NADiR Trial)

Phase 2
Recruiting
Led By Alice Ho, MD, MBA
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Prior progression on immune-checkpoint inhibitor and/or PDL1-negative
ECOG performance status ≤ 1
Must not have
Receipt of >2 lines of chemo in the metastatic setting
Known history of active TB (Bacillus Tuberculosis)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up enrollment to end of treatment up to 5 years
Awards & highlights

Summary

This trial will test to see if the addition of Dostarlimab and Niraparib to Radiation Therapy will be safe and effective in treating participants with metastatic triple negative breast cancer.

Who is the study for?
This trial is for adults with metastatic triple negative breast cancer who need radiation therapy and haven't had a positive response to immune-checkpoint inhibitors or are PDL1-negative. Participants must have good organ function, not be pregnant, agree to use contraception, and can't have certain conditions like active hepatitis, known BRCA mutations, brain metastases, recent major surgery or immunosuppressive treatments.
What is being tested?
The study tests the safety and effectiveness of combining Dostarlimab (an immunotherapy drug) with Niraparib (a PARP inhibitor) alongside standard Radiation Therapy in treating metastatic triple negative breast cancer. The goal is to see if this combination works better than current treatments.
What are the potential side effects?
Possible side effects include fatigue, allergic reactions to medication components, digestive issues such as nausea or constipation from Niraparib; skin reactions from radiation; and immune-related effects like inflammation from Dostarlimab.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer progressed after treatment with immune-checkpoint inhibitors or is PDL1-negative.
Select...
I am fully active and can carry on all my pre-disease activities without restriction.
Select...
I need radiation therapy for symptom relief or to control the cancer's spread.
Select...
I am 18 years old or older.
Select...
I have a tumor that is suitable for radiation therapy.
Select...
I agree to use birth control during and for 3 months after the study.
Select...
I have at least one tumor that can be measured and has not been treated with radiation.
Select...
My breast cancer has spread or come back.
Select...
I can swallow and keep down pills.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have received more than 2 chemotherapy treatments for my cancer after it spread.
Select...
I have an active tuberculosis infection.
Select...
I had a severe reaction to previous immunotherapy.
Select...
I am currently on medication for an infection.
Select...
I have been treated with both a PARP inhibitor and an immune checkpoint inhibitor.
Select...
I have not had any major surgery in the last 3 weeks.
Select...
I have or had lung inflammation or disease needing steroid treatment.
Select...
I have active Hepatitis B or C.
Select...
I have a positive BRCA gene mutation.
Select...
I have active brain metastases or leptomeningeal disease.
Select...
I have been treated for an autoimmune disease in the last 2 years.
Select...
I do not have any serious, uncontrolled medical conditions or active infections.
Select...
I have a history of MDS or AML.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~enrollment to end of treatment up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and enrollment to end of treatment up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall response rate (ORR)-RECIST
Secondary study objectives
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0
Overall response rate (ORR) by irRECIST criteria
Overall survival (OS)
+1 more
Other study objectives
Changes in TILs
ctDNA

Side effects data

From 2022 Phase 2 trial • 37 Patients • NCT03207347
74%
Fatigue
52%
Nausea
39%
Constipation
39%
Anorexia
30%
Anemia
30%
Alkaline phosphatase increased
26%
Weight loss
22%
Dizziness
22%
Insomnia
22%
Dyspnea
22%
Abdominal pain
17%
Headache
17%
Mucositis oral
17%
Platelet count decreased
17%
Creatinine increased
13%
Rash maculo-papular
13%
Vomiting
13%
Aspartate aminotransferase increased
13%
Sinus tachycardia
9%
Urinary tract infection
9%
Cough
9%
Dehydration
9%
Dry mouth
9%
Hypertension
9%
Non-cardiac chest pain
9%
Alanine aminotransferase increased
9%
Anxiety
9%
Blood bilirubin increased
9%
Back pain
4%
Peripheral sensory neuropathy
4%
Postnasal drip
4%
Bruising
4%
Hyperkalemia
4%
Flu like symptoms
4%
Hoarseness
4%
Head injury
4%
Hypokalemia
4%
Hyponatremia
4%
Skin tear
4%
Hyperglycemia
4%
Neutrophil count decreased
4%
Tremor
4%
Esophageal ulcer
4%
Hot flashes
4%
Diarrhea
4%
Depression
4%
Hypotension
4%
Itchy eyes
4%
Oral petechia
4%
Edema limbs
4%
Upper respiratory infection
4%
Leukocytosis
4%
White blood cell decreased
4%
Lung infection
4%
Bloating
4%
Unknown infection
4%
Hematuria
4%
Ascites
4%
Sinus pain
4%
Sore throat
4%
Syncope
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort A
Cohort B

Trial Design

1Treatment groups
Experimental Treatment
Group I: Niraparib + Dostarlimab + Radiation therapyExperimental Treatment3 Interventions
Study cycle length is 3 weeks. Participants will receive: * Niraparib 1x daily during each study cycle * Dostarlimab 1x every 3 weeks for 4 study cycles, then 1x every 6 weeks beginning on Cycle 5 * Radiation therapy will be given on Days 1, 2, and 3 of Cycle 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Niraparib
2018
Completed Phase 4
~2400
Dostarlimab
2020
Completed Phase 3
~1760
Radiation therapy
2013
Completed Phase 3
~2850

Find a Location

Who is running the clinical trial?

University of North CarolinaOTHER
170 Previous Clinical Trials
1,456,036 Total Patients Enrolled
5 Trials studying Breast Cancer
1,341,652 Patients Enrolled for Breast Cancer
Johns Hopkins UniversityOTHER
2,316 Previous Clinical Trials
14,872,791 Total Patients Enrolled
28 Trials studying Breast Cancer
23,519 Patients Enrolled for Breast Cancer
Massachusetts General HospitalLead Sponsor
3,000 Previous Clinical Trials
13,311,467 Total Patients Enrolled
80 Trials studying Breast Cancer
132,859 Patients Enrolled for Breast Cancer

Media Library

Dostarlimab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04837209 — Phase 2
Breast Cancer Research Study Groups: Niraparib + Dostarlimab + Radiation therapy
Breast Cancer Clinical Trial 2023: Dostarlimab Highlights & Side Effects. Trial Name: NCT04837209 — Phase 2
Dostarlimab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04837209 — Phase 2
~4 spots leftby Apr 2025